
    
      This study aims to evaluate the progression free survival after treatment for patient with
      stage I/II supradiaphragmatic HL patient and PET positive after 2 courses of ABVD.

      The treatment consist of 3 phases :

        -  induction treatment with 2 cycles every 3 weeks of bleomycin, etoposide, Adriamycin,
           cyclophosphamide, oncovin, procarbazine, and prednisone (BEACOPP) escalated

        -  radiotherapy 30 Gy starting 3 to 4 weeks after last day of second course of
           BEACOPP-escalated

        -  consolidation treatment with 8 cycles every 21 days of brentuximab vedotin
    
  